Compare Inovio Pharmaceuticals Inc (INO) vs ArcelorMittal SA (MT) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

ArcelorMittal (MT) trades at $65.80, down 0.98% today, with a bullish technical outlook supported by moving averages. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, and maintains a reasonable valuation with a P/E of 17.24 and P/S of 0.81. Recent corporate developments include ongoing share buybacks and a strategic AI collaboration with AWS to enhance operational efficiency.

The outlook for MT is cautiously optimistic, driven by earnings strength and cost initiatives, but faces risks from cyclical steel demand and high capital expenditures. Analyst sentiment is mixed with 50% buy ratings, suggesting potential upside if operational improvements continue, though investors should monitor global economic conditions impacting steel prices.